The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

Valldeoriola, Francesc; Salvador, Antonio; Gómez-Argüelles, J.M.; Marey, José; Moya, Miguel; Ayuga, Ángel; Ramirez, Francisco C.

doi:10.1080/00207454.2017.1387111

Cited by 16 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were replicated by the first RCT to use changes in NMSS total score as a primary outcome, although the latter did not reach statistical significance [36]. In addition, a significant improvement in the mood/ apathy domain was also described in a Spanish observational multicentre study [66]. A recent meta-analysis of eight RCTs (n = 1675) suggested that the use of the rotigotine transdermal patch was associated with improved psychiatric conditions, including depression, as measured by the depression/apathy domain of NMSS and the BDI-II.…”

Section: Depressionmentioning

confidence: 89%

“…The benefits of transdermal rotigotine on sleep disturbances appeared to be sustained for up to 1 year in an open-label study that included 84 completers of the RECOVER study [45]. Sleep fragmentation as measured with the PDSS-2 [64], and self-reported improvement of sleep quality as assessed by PDSS item 1 [65], the Non-Motor Symptoms Questionnaire (NMSQ) [66], or the Pittsburgh Sleep Quality Index [67], improved with rotigotine therapy in open-label studies or studies performed in routine clinical practice settings. There have also been indications that rotigotine might be effective on early-morning off (EMO) symptoms (Sect.…”

Section: Sleep Impairmentmentioning

confidence: 99%

“…Among them, nocturia is a common complaint, with a reported prevalence ranging from 34.6 to 86% [85]. A Spanish observational, retrospective, multisite study reported a positive effect from rotigotine on urinary function and urgency in patients with PD [66], whereas a few open-label either observational or routine clinical practice studies found that nocturia in particular improved with rotigotine [64,65,68,86]. However, specific and detailed studies are still needed so these findings can be translated into clinical practice.…”

Section: Nocturia and Urinary Dysfunctionmentioning

confidence: 99%

See 2 more Smart Citations

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience

et al. 2021

View full text Add to dashboard Cite

Motor and non-motor symptoms (NMS) have a substantial effect on the health-related quality of life (QoL) of patients with Parkinson's disease (PD). Transdermal therapy has emerged as a time-tested practical treatment option, and the rotigotine patch has been used worldwide as an alternative to conventional oral treatment for PD. The efficacy of rotigotine on motor aspects of PD, as well as its safety and tolerability profile, are well-established, whereas its effects on a wide range of NMS have been described and studied but are not widely appreciated. In this review, we present our overall experience with rotigotine and its tolerability and make recommendations for its use in PD and restless legs syndrome, with a specific focus on NMS, underpinned by level 1-4 evidence. We believe that the effective use of the rotigotine transdermal patch can address motor symptoms and a wide range of NMS, improving health-related QoL for patients with PD. More specifically, the positive effects of rotigotine on non-motor fluctuations are also relevant. We also discuss the additional advantages of the transdermal application of rotigotine when oral therapy cannot be used, for instance in acute medical emergencies or nil-by-mouth or pre/post-surgical scenarios. We highlight evidence to support the use of rotigotine in selected cases (in addition to general use for motor benefit) in the context of personalised medicine.

show abstract

Section: Depressionmentioning

confidence: 89%

Section: Sleep Impairmentmentioning

confidence: 99%

Section: Nocturia and Urinary Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several studies have shown rotigotine efficacy on non-motor symptoms 13,[26][27][28][29] , including mood and apathy. However, these studies concerned more advanced PD patients and, were not specifically designed to assess apathy and neuropsychiatric Table 3.…”

Section: Discussionmentioning

confidence: 99%

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD

Castrioto

Thobois

Anheim

et al. 2020

npj Parkinsons Dis.

View full text Add to dashboard Cite

Management of apathy, depression and anxiety in Parkinson’s disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (p = 0.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms.

show abstract

“…Rotigotine has been reported to improve sleep quality [32]. The improvement in abnormal circadian rhythm might be attributed to an improvement in motor function [33] and enhancement of the patients’ sleep quality at night [34]. …”

Section: Discussionmentioning

confidence: 99%

Rotigotine Improves Abnormal Circadian Rhythm of Blood Pressure in Parkinson’s Disease

Oka

Nakahara

Umehara³

2018

Eur Neurol

View full text Add to dashboard Cite

Introduction: Cardiovascular autonomic failure is commonly associated with Parkinson’s disease (PD), affecting the daily lives of patients. Rotigotine was recently reported not to influence cardiovascular autonomic responses in contrast to other dopaminergic drugs. The effect of rotigotine on daily blood pressure (BP) fluctuations might reflect autonomic failure in patients with PD. Methods: Twenty-five PD patients who were receiving rotigotine and 12 patients not receiving rotigotine were recruited. Systolic BP during the daytime and nighttime was measured by 24-h BP monitoring at an interval of 2 years. The patients were divided into 3 groups according to the BP fluctuation type: dippers (nocturnal fall in BP ≥10%), non-dippers (0–10%), and risers (< 0%). The time course of BP was compared between the patients given rotigotine and those not given rotigotine. Results: Among the 25 patients who received rotigotine, the BP type worsened in 2 patients, was unchanged in 16 patients, and improved in 7 patients. Among the 12 patients who were not receiving rotigotine, the BP type worsened in 5 patients, was unchanged in 4 patients, and improved only in 3 patients (p = 0.042). Conclusion: Rotigotine improves the abnormal circadian rhythm of BP in patients with PD. Rotigotine was suggested to have favorable effects on cardiovascular autonomic responses and circadian rhythm in patients with PD.

show abstract

The effects of transdermal rotigotine on non-motor symptoms of Parkinson's disease: a multicentre, observational, retrospective, post-marketing study

Abstract: In clinical practice in Spain, rotigotine may be an effective treatment to reduce the non-motor and motor symptoms in patients with advanced Parkinson's disease.

Cited by 16 publications

References 19 publications

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience

Rotigotine Transdermal Patch for Motor and Non-motor Parkinson’s Disease: A Review of 12 Years’ Clinical Experience

A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD

Rotigotine Improves Abnormal Circadian Rhythm of Blood Pressure in Parkinson’s Disease

Contact Info

Product

Resources

About